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Inequalities in reported cancer patient experience by socio-demographic characteristic and cancer site:
evidence from respondents to the English Cancer Patient Experience Survey
Patient experience is a critical dimension of cancer care quality. Understanding variation in experience among
patients with different cancers and characteristics is an important first step for designing targeted improve-
ment interventions. We analysed data from the 2011/2012 English Cancer Patient Experience Survey (n =
69 086) using logistic regression to explore inequalities in care experience across 64 survey questions. We
additionally calculated a summary measure of variation in patient experience by cancer, and explored inequali-
ties between patients with cancers treated by the same specialist teams. We found that younger and very old,
ethnic minority patients and women consistently reported worse experiences across questions. Patients with
small intestine/rarer lower gastrointestinal, multiple myeloma and hepatobiliary cancers were most likely to
report negative experiences whereas patients with breast, melanoma and testicular cancer were least likely
(top-to-bottom odds ratio = 1.91, P < 0.0001). There were also inequalities in experience among patients with
cancers treated by the same specialty for five of nine services (P < 0.0001). Specifically, patients with ovarian,
multiple myeloma, anal, hepatobiliary and renal cancer reported notably worse experiences than patients with
other gynaecological, haematological, gastrointestinal and urological malignancies respectively. Initiatives to
improve cancer patient experience across oncology services may be suitably targeted on patients at higher risk
of poorer experience.
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INTRODUCTION
Patient experience is a central dimension of healthcare
quality (IOM 2001; ASCO 2006; Ludwig et al. 2006; NHS
2013–2014). Consequently, measurement of patient expe-
rience in large nationwide samples of patients is becoming
common practice in several countries. For example, in the
United States, the Hospital Consumer Assessment of
Healthcare Providers and Systems survey measures the
experience of over a million hospital patients every year
(Goldstein et al. 2005; Medicare.Gov 2014). A potential
barrier in translating patient experience information into
improvement actions is that data often relate to patients
with a wide spectrum of conditions. Patients with cancer,
in particular, have very different care pathways compared
with other inpatients with non-neoplastic disease (e.g.,
elective surgery patients or those with exacerbations of a
chronic disease). Therefore, experience surveys of patients
with cancer are increasingly being considered in different
countries (Iversen et al. 2012; Evensen et al. 2013;
Garfinkel et al. 2013).
In England, a national programme of repeatable surveys
specifically dedicated to the measurement of the experi-
ence of patients with cancer was introduced recently
(Department of Health 2011–2012a). Cancer charities and
consumer groups strongly support and engage with the
dissemination of the results of these surveys, which cover
a wide spectrum of items on different domains of experi-
ence (Macmillan Cancer Support 2012–2013). Because this
survey encompasses patients with any type of cancer, it
provides an opportunity to explore variation among
patients with different diagnoses (including common,
rarer and rare cancers; Department of Health 2011–2012a;
Lyratzopoulos et al. 2012b; El Turabi et al. 2013).
Appreciating how patient experience varies among
patients with different socio-demographic characteristics,
and crucially, different cancers, is an important first step in
helping to understand responsible mechanisms and the
development of targeted interventions for improvement.
Because large national surveys of the experience of patients
with many different cancers are a recent development, our
current understanding of variation in experience by cancer
diagnosis is limited. The ease and speed by which a diag-
nosis can be established, the treatment burden and the
prognosis of different cancers vary substantially. We would
hypothesise that the experience of care will vary substan-
tially among patients with different cancers; specifically,
patients with prolonged diagnostic intervals, higher treat-
ment burden and worse prognosis may provide more criti-
cal evaluations of their care. Although inequalities in
reported experience among socio-demographic groups may
be driven by differential prior expectations of quality, vari-
ation in experience among patients with different cancers
should be relatively robust to such confounding, more
directly reflecting disease factors.
Further, as results for the Cancer Patient Experience
Survey are reported publicly for each survey item, we were
a priori interested in potential inequalities in respect of
each survey item; and on the degree of consistency in
patterns of variation across different research questions
and aspects of experience.
With these prior considerations, we analysed data from
the English Cancer Patient Experience Survey 2011/2012
to explore variation in the experience of care between
patients with cancer for all survey questions. Specifically,
our objective was to describe and summarise variation in
patient experience by age, gender, deprivation, ethnicity
and cancer diagnosis across all survey questions.
METHODS
Data
We used anonymous data from the Cancer Patient Expe-
rience Survey 2011/2012, a national postal survey of
patients with cancer treated in English National Health
Service hospitals commissioned by the UK Department of
Health and undertaken by Quality Health (Chesterfield,
UK), a specialist survey provider (Department of Health
2011–2012a). Patients were included in the survey sam-
pling frame if cancer was recorded as the primary diagno-
sis in any hospital care record during September to
November 2011. Primary data collection for the survey
was approved by the Ethics and Confidentiality Commit-
tee of the National Information Governance Board (refer-
ence ECC 3-04(d)/2011; Department of Health 2011–
2012a). Anonymous data from the survey are available for
not-for-profit research from the UK Data Archive (http://
www.data-archive.ac.uk/) – the source of data used in the
present study (Department of Health 2011–2012b).
The survey questionnaire included evaluative questions
that covered patient experience along the care pathway
of patients with cancer, encompassing experience of presen-
tation, diagnostic testing, treatment decisions, doctor and
nurse communication, informational integration between
hospital and community services after discharge, experience
of chemotherapy and radiotherapy treatment, and outpa-
tient follow-up care (Appendix 1). Cognitive testing of
survey items was carried out by the survey provider in
panels of volunteers identified by Macmillan Cancer
Support, a national cancer charity (Department of Health
2011–2012a). The same postal methodology used for the
final survey was used during cognitive testing, with
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interview follow-up. Testing encompassed the assessment
of patients’ ability to complete the questionnaire, their
understanding of questions and general exploration of
patient views about the survey.
Most questions had four or five ordered (Likert)
response options, ranging from very positive to very
negative experience, although some report-type ques-
tions had a binary (Yes/No) format. For each survey
question, public reporting is based on the proportion of
patients who provided responses indicating ‘good’ or
‘very good’ experience (Department of Health 2011–
2012a). As this is how the survey findings are used by
clinicians and managers to inform quality improvement
efforts, and also by members of the public when access-
ing information about the comparative performance of
different English hospitals, in this analysis, we used the
same binary categorisation of experience (positive/
negative) as used in public reporting.
Hospital record recorded cancer diagnosis classified
using the International Classification of Diseases 10th
edition (ICD-10) diagnostic code, patient age and gender,
and hospital of treatment were available for all respond-
ents. Self-reported ethnic group information was used in
the analysis (Office of National Statistics classification) as
the gold-standard approach to ethnic group assignment
(Saunders et al. 2013). Therefore, and in the context of
highly complete information (96.3%), the analysis was
restricted to survey respondents for whom information on
self-reported ethnicity was available. Age was categorised
into eight groups (16–24, 25–34 in 10 year groups to 75–84
and 85+). Socio-economic status information was not
available in the 2011/2012 dataset; however, patients’ dep-
rivation score (Index of Multiple Deprivation 2007 score of
lower super output area of residence) was available for the
2010 survey (Indices of Deprivation 2007; Department of
Health 2010). Consequently, in supplementary analysis,
we examined socio-economic inequalities in cancer
patient experience using the latter dataset.
We included patients with any cancer, using 36 diagno-
sis groups based on the ICD-10 classification (Table 1;
Appendix 2). Of these, 31 were further nested within nine
specialty groups (also called ‘multidisciplinary team’ or
MDT groups in the United Kingdom and in other Euro-
pean countries, e.g., urological, gynaecological or
haematological specialty groups) (European Partnership
Action Against Cancer Consensus Group et al. 2014).
Specialty groups encompass patients with cancers typi-
cally treated by the same oncology service and within
shared premises (e.g., wards or outpatient clinics); these
patients are also often treated by the same multidiscipli-
nary group of oncologists, surgeons, nurses and other
Table 1. Socio-demographic and clinical characteristics of survey
respondents
Age All %
16–24 355 0.5
25–34 954 1.4
35–44 2,999 4.3
45–54 8,911 12.9
55–64 16,970 24.6
65–74 22,749 32.9
75–84 13,564 19.6
85+ 2,584 3.7
Gender
Men 32,463 47.0
Women 36,623 53.0
Ethnic group
White 66,421 96.1
Mixed 278 0.4
Asian 1,146 1.7
Black 949 1.4
Chinese 150 0.2
Other 142 0.2
Deprivation
Most affluent 14,589 21.1
2nd 14,624 21.2
3rd 13,582 19.7
4th 11,566 16.7
Most deprived 9,409 13.6
Cancer diagnosis
Anal 242 0.4
Bladder 6,503 9.4
Bone sarcoma 174 0.3
Brain 483 0.7
Breast 13,396 19.4
Cervical 405 0.6
Colon 5,054 7.3
Ductal carcinoma in situ 916 1.3
Endometrial 1,478 2.1
Gynaecological NOS 88 0.1
Hepato-biliary 568 0.8
Hodgkin lymphoma 487 0.7
Laryngeal 361 0.5
Leukaemia 2,479 3.6
Lung 3,698 5.4
Melanoma 1,546 2.2
Mesothelioma 392 0.6
Multiple myeloma 3,236 4.7
Non-Hodgkin lymphoma 4,290 6.2
Oesophageal 1,362 2
Ophthalmic and rarer CNS 59 0.1
Oropharyngeal 1,280 1.9
Ovarian 1,823 2.6
Pancreatic 673 1
Prostate 5,568 8.1
Rectal 3,541 5.1
Renal 950 1.4
Secondary 4,308 6.2
Small-intestine 215 0.3
Soft tissue sarcoma 575 0.8
Stomach 1,019 1.5
Testicular 256 0.4
Thyroid 493 0.7
Ureter and rarer urological 349 0.5
Vulval / vaginal 236 0.3
Any other cancer diagnosis 583 0.8
Ethnic group was defined using a six-group classification (White, Mixed, Asian or
Asian British, Black or Black British, Chinese and Other).
Deprivation quintile groups (for data from the 2010 survey only) were defined by
applying national (England) quintile-defining points (8.257, 13.525, 20.741, and
33.511) to Index of multiple deprivation (IMD) scores.
ICD-10 diagnostic codes. Anal C21; Bladder C67; Bone sarcoma C40, C41; Brain C71;
Breast C50; Cervical C53; Colon C18; Ductal carcinoma in situ (DCIS) D05;
Endometrial C54, C55; Gynaecological not otherwise specified (Gynaecological NOS)
C57; Hepato-biliary C22, C23, C24; Hodgkin lymphoma C81; Laryngeal C32;
Leukaemia C91, C92, C93, C94, C95; Lung C34, C33; Melanoma C43;
Mesothelioma C45; Multiple myeloma C90; Non-Hodgkin lymphoma C82, C83,
C85, C84; Oesophageal C15; Ophthalmic and rarer central nervous system (CNS)
C47, C69, C70, C72; Oropharyngeal C00 – C14, C30, C31; Ovarian C56; Pancreatic
C25; Prostate C61; Rectal C19, C20; Renal C64; Secondary C77, C78, C79;
Small-intestine C17, C26; Soft tissue sarcoma C48, C49, C46; Stomach C16;
Testicular C62; Thyroid C73; Ureter and rarer urological C60, C63, C65, C66, C68;
Vulval / vaginal C51, C52; Any other cancer diagnosis C37, C38, C39, C74, C75,
C76, C80, C97, C58, C88, C96.
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healthcare professionals, specialising in the treatment of
cancers of the same body system (Table 2; Appendix 2).
Analysis
Initially, we calculated the unadjusted proportion of posi-
tive responses for each question and by each variable
group. Then, for each (of 65) evaluative questions sepa-
rately, we fitted a mixed-effect logistic regression model
with positive/negative experience categories as the
outcome, and adjusting for age group, sex, ethnicity and
cancer diagnosis as categorical variables. A random effect
for hospital of treatment was also included in these
models, to account for potential confounding by differen-
tial concentration of patients with different characteris-
tics (e.g., ethnic minority patients) in differentially
performing hospitals. For one question (question 28,
whether a patient was happy to be asked to take part in
research) the model did not converge, and this question
was excluded from further analyses; patient experience for
this question was highly positive (95.5%).
We visually summarised patterns of inequality across all
questions – similar approaches for visually summarising
multiple observations across many cancer sites have been
used previously (Moller et al. 2009). By survey question, for
each variable we assigned ranks to each one of its categorical
groups (i.e., among the 36 cancers, we assigned ranks of 1 and
36 to those cancers associated with the best and worst
reported experience, respectively, and similarly for all other
variable categories by question). We subsequently used a
red-amber-green colour coding convention (red = most nega-
tive experience rank/group, green = most positive experi-
ence rank/group) to further visually summarise the findings
across questions, reporting odds ratios (ORs) and a rank-
based colour code. We used a joint (Wald) test to examine
whether each variable improved the fit of model to the data,
and where it did not we did not apply the colour coding.
Subsequently, as we observed overall consistent patterns
of inequalities in patient experience by cancer, we estimated
the average association between cancer diagnosis and
patient experience across the entire survey. For this analysis
we included all responses to all questions and adjusted for
question to account for the fact that the proportion of
patients reporting positive experience varies by question;
and that some questions do not apply to all patients (see
Appendix 1). We also adjusted for age, gender and ethnicity,
and accounted for within-respondent correlation of
responses using a linear regression within a generalised
estimating equation approach. This approach increases
power to explore within specialty group (i.e., within MDT)
variation, enabling us to better distinguish inequalities even
between cancers with relatively small sample sizes. To
explore whether there are inequalities in cancer patient
experience among patients with cancers treated by the same
specialty groups we tested the equality of ORs for diagnoses
within each specialty group using a Wald test.
We chose the largest cancer diagnosis group with
approximately balanced gender distribution (rectal) as the
baseline, while for further analysis comparing cancer
experience within specialty group, we chose the largest
bi-gender cancer diagnosis in each group. All analyses
were carried out using Stata 11.2 (StataCorp. 2009. Stata
Statistical Software: Release 11. College Station, TX:
StataCorp LP). Colour coding was applied using MS Excel
2010 (Microsoft Excel (2010) [computer software]).
RESULTS
Of an initial total of 113 808 patients, 71 793 completed
the survey (a response rate of 68%, after excluding
patients who died soon after their inclusion in the sam-
pling frame); 69 086 responses with valid self-reported eth-
nicity were included in the final analysis sample.
The sample characteristics and number of responses by
survey question are shown in Table 1 and Appendix 1.
The unadjusted proportion of patients reporting positive
experience ranged from 24% (q68 – was the patient offered
a written care plan) to 95% (q63 – correct patient records
available at outpatient appointment).
Hereafter and unless otherwise noted, the adjusted ORs
for reporting a more negative experience of care compared
with the baseline group are presented for question 70 (overall
rating of care, Table 2). The results for this question are a
typical reflection of inequalities observed in respect of other
survey questions (Tables 3 and 4 and Appendix 3).
Patients in the 65–74-year group reported a positive
experience more often than any other age group, while
younger patients, and also the very old, reported compara-
tively poorer experience. Patients from ethnic minorities
and women were also more likely to report poor experi-
ence (P < 0.0001 for all).
There was also evidence (P < 0.0001) of considerable
inequalities in experience across cancer diagnoses, with
patients with ductal carcinoma in situ and breast cancer
being the most likely to report positive experiences and
patients with thyroid and hepatobiliary cancer the least
likely to do so [OR for negative experience compared with
rectal cancer; ductal carcinoma in situ OR = 0.40 (95%
confidence interval 0.31–0.53), breast OR = 0.55 (0.48–0.62),
thyroid OR = 1.44 (1.12–1.84), hepatobiliary cancer OR =
1.46 (1.14–1.87) ]. There was evidence (P < 0.05) of inequali-
ties within cancer specialty for four of the nine specialty
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Table 3. Association between patient socio-demographic characteristics and cancer patient experience
Age Sex Ethnicity Deprivation
16
-2
4
25
-3
4
35
-4
4
45
-5
4
55
-6
4
65
-7
4
75
-8
4
85
+
M
en
W
om
en
W
h
it
e
M
ix
ed
A
si
an
B
la
ck
C
h
in
es
e
O
th
er
A
ff
lu
en
t
2n
d
3r
d
4t
h
D
ep
ri
ve
d
1 Saw GP once/twice before being told had to go to hospital 2.1 1.7 1.6 1.4 1.3 ref 0.9 0.9 ref 1.3 ref 1.4 2.2 1.9 1.6 1.8 ref 1.0 1.0 1.0 1.1
2 Patient thought they were seen as soon as necessary 2.1 2.6 2.0 1.5 1.3 ref 0.9 0.8 ref 1.1 ref 1.3 2.2 1.3 1.8 3.2 ref 1.0 1.0 0.9 0.9
3 % saw a hospital doctor in less than 3 months 2.1 2.1 1.6 1.4 1.2 ref 1.0 1.0 ref 1.2 ref 1.3 1.6 1.4 1.6 1.7 ref 1.0 1.0 1.1 1.1
4 Patient's health got better or remained about the same while waiting 2.2 2.0 1.9 1.6 1.3 ref 0.9 0.9 ref 1.1 ref 1.2 1.8 1.4 1.7 1.7 ref 1.0 1.0 1.1 1.3
6 Staff gave complete explanation of purpose of test(s) 1.6 1.4 1.4 1.2 1.0 ref 1.2 1.8 ref 1.2 ref 1.5 1.2 1.6 1.8 1.0 ref 0.9 1.0 1.0 0.9
7 Staff explained completely what would be done during test 2.0 1.5 1.6 1.3 1.1 ref 1.2 1.8 ref 1.2 ref 1.5 1.3 1.6 2.2 1.4 ref 0.9 1.0 1.0 1.0
8 Given easy to understand written information about test 1.4 1.1 1.2 1.0 1.0 ref 1.4 2.0 ref 1.0 ref 1.5 1.6 1.7 2.7 1.8 ref 1.0 1.1 1.2 1.2
9 Given complete explanation of test results in understandable way 1.7 2.0 1.6 1.6 1.2 ref 1.1 1.3 ref 1.0 ref 1.2 1.3 1.8 2.6 1.8 ref 1.0 1.1 1.0 1.0
11 Patient told they could bring a friend when first told they had cancer 0.9 1.4 1.9 1.6 1.4 ref 0.8 0.8 ref 1.3 ref 0.8 0.8 1.1 0.6 0.8 ref 1.0 0.9 0.8 0.7
12 Patient felt they were told sensitively that they had cancer 1.7 1.5 1.5 1.6 1.3 ref 0.7 0.6 ref 1.3 ref 1.0 1.2 0.9 0.8 1.2 ref 1.0 0.9 0.9 0.8
13 Patient completely understood the explanation of what was wrong 2.9 2.5 2.2 1.7 1.3 ref 0.9 1.2 ref 1.1 ref 1.1 1.0 1.4 1.6 1.3 ref 1.1 1.1 1.0 1.1
14 Patient given written information about the type of cancer they had 1.1 1.1 1.3 1.2 1.1 ref 1.2 1.6 ref 1.2 ref 1.2 1.2 1.5 1.9 1.4 ref 1.0 1.0 1.0 1.0
15 Patient given a choice of different types of treatment 1.0 1.2 1.5 1.3 1.1 ref 1.1 1.1 ref 1.1 ref 1.5 1.1 1.3 2.3 1.4 ref 1.0 1.1 1.1 1.1
16 Patient thinks their views were taken into account when discussing 1.5 1.5 1.4 1.4 1.2 ref 1.0 1.1 ref 1.0 ref 1.2 1.1 1.3 1.7 1.2
17 Possible side effects explained in an understandable way 1.0 0.9 1.0 1.0 1.0 ref 1.2 1.6 ref 1.1 ref 1.4 1.1 1.4 1.7 1.0 ref 1.0 1.0 1.0 1.0
18 Patient given written information about side effects 0.7 0.7 0.6 0.7 0.8 ref 1.6 3.2 ref 1.1 ref 1.7 1.3 1.4 1.6 1.4 ref 1.0 1.0 1.1 1.2
19 Patient definitely involved in decisions about which treatment 1.7 1.6 1.5 1.4 1.2 ref 1.0 1.2 ref 1.1 ref 1.4 1.2 1.7 1.8 1.5 ref 1.0 1.1 1.0 1.0
20 Patient given the name of the CNS in charge of their care 0.6 0.9 1.1 1.0 1.0 ref 1.4 2.2 ref 1.0 ref 1.0 1.2 0.9 1.4 1.3 ref 1.0 1.0 1.0 0.9
21 Patient finds it easy to contact their CNS 1.3 1.4 1.4 1.3 1.2 ref 0.9 0.8 ref 1.1 ref 1.1 1.3 1.1 1.5 1.3 ref 1.0 1.0 0.9 0.9
22 CNS definitely listened carefully the last time spoken to 1.3 1.7 1.5 1.5 1.3 ref 0.9 1.1 ref 1.2 ref 1.0 1.4 1.2 2.0 1.4 ref 1.0 1.1 1.0 1.0
23 Get understandable answers to important questions all/most of the time 
( )
1.2 1.6 1.5 1.3 1.1 ref 1.1 1.2 ref 1.0 ref 1.3 2.2 1.5 3.5 1.0 ref 1.1 1.1 1.2 1.4
24 Hospital staff gave information about support groups 0.7 1.2 1.2 1.2 1.1 ref 1.1 1.7 ref 1.6 ref 1.0 1.2 1.2 1.3 1.0 ref 1.0 1.0 1.0 1.1
25 Hospital staff gave information on getting financial help 0.2 0.6 0.8 0.8 0.9 ref 1.1 1.3 ref 1.2 ref 0.9 1.1 0.9 1.3 1.0 ref 1.0 1.0 1.0 0.9
26 Hospital staff told patient they could get free prescriptions 2.6 3.0 3.4 3.7 3.1 ref 0.8 0.7 ref 1.4 ref 1.0 0.9 1.1 0.9 0.9 ref 1.0 0.9 0.8 0.8
27 Patient asked if they would like to take part in cancer research 0.7 0.7 0.9 0.8 0.8 ref 1.7 3.2 ref 1.2 ref 0.8 0.9 0.8 1.2 0.9
29 Patient would have liked to have been asked 0.5 0.2 0.3 0.4 0.6 ref 1.6 2.5 ref 1.2 ref 0.9 1.2 1.0 1.8 1.1
31 Admission date not changed by hospital 1.2 1.1 1.0 1.0 0.9 ref 1.1 1.4 ref 0.9 ref 1.8 1.6 1.2 0.5 1.8 ref 1.0 1.1 1.1 1.1
32 Staff gave complete explanation of what would be done 1.5 1.1 1.2 1.1 1.1 ref 1.2 1.7 ref 1.3 ref 0.9 1.0 1.3 1.2 2.8 ref 1.0 1.1 1.0 1.1
33 Patient given written information about the operation 1.1 0.7 0.8 0.9 1.0 ref 1.4 2.1 ref 1.2 ref 1.0 1.1 0.7 1.4 1.2 ref 1.0 1.0 1.0 1.0
34 Staff explained how operation had gone in understandable way 1.5 1.5 1.5 1.5 1.3 ref 1.1 1.4 ref 1.2 ref 1.3 1.3 1.3 2.0 2.1 ref 1.0 1.0 1.0 1.0
36 Got understandable answers to important questions all/most of the time 2.0 1.9 1.7 1.5 1.2 ref 1.2 1.4 ref 1.0 ref 1.4 1.6 1.6 2.2 1.8 ref 1.0 1.1 1.1 1.3
37 Patient had confidence and trust in all doctors treating them 2.5 2.1 2.0 1.6 1.4 ref 0.9 0.8 ref 1.3 ref 1.3 1.3 1.6 2.0 2.0 ref 0.9 0.9 0.9 0.9
38 Doctors did not talk in front of patient as if they were not there 1.6 1.6 1.4 1.3 1.1 ref 1.2 1.5 ref 0.9 ref 1.2 2.4 1.3 1.5 1.5 ref 1.0 1.1 1.2 1.3
39 Patient's family definitely had opportunity to talk to doctor 1.4 2.4 2.0 1.9 1.4 ref 0.9 1.0 ref 1.1 ref 0.8 0.8 0.7 0.8 1.2 ref 0.9 1.0 0.9 0.9
40 Got understandable answers to important questions all/most of the time 1.7 1.6 1.5 1.4 1.2 ref 1.1 1.4 ref 1.2 ref 1.6 1.6 1.4 2.0 1.7 ref 1.0 1.0 1.1 1.1
41 Patient had confidence and trust in all ward nurses 1.7 1.6 1.6 1.4 1.2 ref 0.9 1.0 ref 1.4 ref 1.3 1.2 1.3 1.4 1.3 ref 1.0 0.9 0.9 0.7
42 Nurses did not talk in front of patient as if they were not there 1.5 1.6 1.5 1.4 1.1 ref 1.2 1.6 ref 1.0 ref 1.8 2.9 1.5 2.0 2.4 ref 1.0 1.1 1.1 1.2
43 Always / nearly always enough nurses on duty 2.2 1.8 1.8 1.6 1.3 ref 0.8 0.9 ref 1.3 ref 1.1 1.1 1.0 1.2 1.3 ref 1.1 1.0 1.0 0.9
44 Patient did not think hospital staff deliberately misinformed them 2.4 2.0 1.9 1.6 1.3 ref 1.1 1.6 ref 1.0 ref 2.3 2.5 2.5 2.4 2.7 ref 1.1 1.2 1.3 1.4
45 Patient never thought they were given conflicting information 2.7 2.2 2.2 1.8 1.4 ref 0.9 0.9 ref 1.1 ref 1.2 1.1 1.0 0.8 0.9 ref 1.0 1.0 1.0 1.0
46 Hospital staff asked what name the patient preferred to be called by 1.5 2.0 1.9 1.8 1.4 ref 0.8 0.8 ref 1.4 ref 1.4 1.2 1.4 0.9 1.7
47 Always given enough privacy when discussing condition/treatment 2.3 2.0 2.0 2.0 1.6 ref 0.8 0.8 ref 1.5 ref 1.2 1.1 1.2 1.0 1.1 ref 1.0 1.0 0.9 0.9
48 Always given enough privacy when being examined or treated 3.2 2.7 2.5 2.1 1.5 ref 0.8 1.2 ref 1.2 ref 1.1 1.0 1.1 1.3 0.7 ref 1.0 0.9 0.9 0.9
49 Patient was able to discuss worries and fears with staff 1.6 1.8 1.8 1.7 1.3 ref 1.1 1.2 ref 1.5 ref 1.3 1.6 1.3 1.7 2.6
50 Hospital staff did everything to help control pain all of the time 3.1 2.4 2.2 1.9 1.4 ref 1.0 1.3 ref 1.2 ref 1.5 1.7 1.1 1.1 1.2 ref 1.0 1.0 1.0 1.0
51 Always treated with respect and dignity by staff 1.8 2.0 1.5 1.6 1.2 ref 0.9 1.1 ref 1.3 ref 1.2 1.4 1.1 1.7 1.3 ref 1.0 0.9 0.9 0.9
52 Given clear written information about what should / should not do post 0.9 1.8 1.3 1.3 1.2 ref 1.0 1.3 ref 1.3 ref 0.9 0.8 0.8 1.1 1.6 ref 0.9 0.9 0.8 0.8
53 Staff told patient who to contact if worried post discharge 0.9 1.7 1.4 1.2 1.1 ref 1.1 1.8 ref 1.4 ref 0.5 0.9 0.9 1.3 1.1 ref 1.1 1.1 1.0 1.1
54 Family definitely given all information needed to help care at home 0.9 1.8 1.8 1.6 1.3 ref 0.9 0.9 ref 1.5 ref 1.0 0.7 0.9 1.1 1.2 ref 1.0 0.9 0.9 0.8
55 Patient definitely given enough care from health or social services 1.0 1.8 1.6 1.4 1.2 ref 1.0 1.1 ref 1.3 ref 1.5 1.5 1.3 1.6 1.8 ref 1.0 1.1 1.1 1.1
56 Staff definitely did everything to control side effects of radiotherapy 1.6 1.6 1.2 1.1 1.0 ref 1.1 1.1 ref 1.2 ref 1.4 1.6 1.8 2.2 1.0 ref 0.9 0.9 0.9 0.8
57 Staff definitely did everything to control side effects of chemotherapy 1.3 1.4 1.3 1.1 1.1 ref 1.1 1.6 ref 1.1 ref 1.2 1.8 1.5 1.5 1.8
58 Staff definitely did everything they could to help control pain 1.7 1.5 1.3 1.2 1.1 ref 1.2 1.5 ref 1.2 ref 1.3 1.7 1.5 1.6 1.6 ref 0.9 1.0 0.9 0.9
59 Hospital staff definitely gave patient enough emotional support 1.6 2.0 2.0 1.9 1.5 ref 0.9 0.9 ref 1.3 ref 1.2 1.3 1.4 1.4 1.4 ref 1.0 0.9 0.9 0.9
61 Waited no longer than 30 minutes for OPD appointment to start 1.5 1.8 1.9 1.4 1.2 ref 0.9 0.8 ref 1.1 ref 1.4 1.1 0.9 1.4 1.4 ref 1.0 0.9 0.9 0.8
62 Patient thought doctor spent about the right amount of time with them 2.1 2.4 2.4 1.8 1.4 ref 1.0 1.1 ref 1.2 ref 0.6 1.9 1.5 1.6 1.3 ref 1.0 1.1 1.1 1.2
63 Doctor had the right notes and other documentation with them 1.7 2.1 1.6 1.5 1.4 ref 0.8 0.6 ref 0.9 ref 0.5 1.1 0.7 0.9 1.5 ref 0.9 0.9 0.9 0.9
64 GP given enough information about patient's condition and treatment 2.6 2.5 1.9 1.6 1.4 ref 0.8 1.0 ref 1.2 ref 1.5 2.1 1.3 3.5 3.0 ref 1.0 1.1 1.1 1.4
65 Practice staff definitely did everything they could to support patient 1.9 1.7 1.4 1.3 1.2 ref 0.9 1.0 ref 1.2 ref 1.4 1.3 1.3 1.8 1.8 ref 1.0 1.0 1.1 1.2
66 Hospital and community staff always worked well together 2.0 2.2 1.9 1.7 1.4 ref 0.9 1.0 ref 1.2 ref 1.1 1.6 1.3 1.5 2.1 ref 0.9 0.9 0.9 0.8
67 Given the right amount of information about condition and treatment 1.4 1.9 1.9 1.7 1.3 ref 1.0 1.3 ref 1.2 ref 1.5 1.2 1.4 2.3 1.7 ref 1.0 1.1 1.1 1.2
68 Patient was offered a written care plan 1.2 1.8 1.8 1.5 1.2 ref 0.9 1.0 ref 1.1 ref 0.8 0.5 0.5 0.8 0.7
69 Patient did not feel that they were treated as a set of cancer symptoms 1.6 1.8 1.7 1.6 1.4 ref 0.8 0.9 ref 1.2 ref 1.7 2.1 1.2 2.0 2.5 ref 1.0 1.0 1.1 1.2
70 Overall rating of care 1.8 1.7 1.7 1.4 1.3 ref 1.1 1.5 ref 1.3 ref 1.5 2.7 2.3 3.5 2.3 ref 1.0 1.0 1.0 1.1
Absence of colour coding indicates lack of statistical evidence of variation.
CNS, clinical nurse specialist; GP, general practitioner; OPD, outpatients department.
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groups. For example, among patients with haematological
cancers, patients with multiple myeloma were most likely
to report poor experience (OR compared with non-Hodgkin
lymphoma patients 1.56, 95% confidence interval 1.34–
1.82) and within the urology group, compared with patients
with bladder cancer, patients with testicular cancer had
substantially lower odds of reporting a negative overall expe-
rience (OR = 0.59, 95% confidence interval 0.39–0.89) –
noting that this difference was adjusted for age.
To aid interpretation, the full crude and case-mix
adjusted proportions of patients reporting a negative expe-
rience by variable category (age group, gender, ethnic
group and cancer diagnosis) for question 70 are shown in
Appendix 4. For example, the case-mix adjusted propor-
tion of participants reporting a negative experience was
6% and 8% for patients with ductal carcinoma in situ or
breast cancer, whereas it was 18% and 19% for patients
with thyroid and hepatobiliary cancer respectively.
Visual summaries of inequalities in patient experience
by age, gender, deprivation, ethnic group and cancer diag-
nosis across survey questions is provided by Tables 3 and
4 and Appendix 3. A brief summary is presented in Box 1.
Questions are grouped by domain of care (full details in
Appendix 1).
Lastly, given overall consistent inequalities across ques-
tions, we examined the average experience of patients
across the whole survey. We found significant variation in
patient experience by socio-demographic characteristics (P
< 0.0001 for all), cancer diagnosis (Fig. 1, P < 0.0001) and
within cancer specialty group (Fig. 2, P < 0.0001 for five of
nine specialty groups, Appendix 5–7). On average, patients
with ductal carcinoma in situ, breast cancer and melanoma
report the most positive patient experience and those with
anal, hepatobiliary, multiple myeloma and small-intestine
cancers the least positive, overall consistent with the pat-
terns observed across individual questions. Regarding
inequalities within cancer specialty groups, patients with
endometrial cancer tended to report more positive experi-
ence than patients with ovarian cancer [OR for reporting a
poor experience = 0.81 (0.75–0.86), P < 0.0001]. There was
also heterogeneity in experience among patients with
haematological malignancies (P < 0.0001), with patients
with multiple myeloma reporting the poorest experience
[OR for reporting a poorer experience = 1.25 (1.19–1.31)
compared with patients with non-Hodgkin lymphoma].
Patients with anal, hepatobiliary and renal cancer also
tended to report notably worse experiences compared with
patients with other gastrointestinal and urological cancers
respectively (P < 0.001).
DISCUSSION
Using data from a large nationwide survey with a rela-
tively high response rate, we describe overall consistent
inequalities in the experience of patients with cancer
across different survey items. Younger and very old
patients and those belonging to ethnic minorities tended
to evaluate their care experience more critically across the
great majority of questions; to a lesser degree, this is also
true for women. There were overall consistent differences
in experience among patients with different cancers. For
example, among patients with 36 distinct diagnostic
groups, patients with melanoma and breast cancer tended
to most often report positive experiences and those with
hepatobiliary cancer and multiple myeloma were more
likely to report negative experiences. Further, there were
also substantial differences among patients with different
cancers treated by the same clinical specialties, and
therefore, within the same MDT service environments.
Specifically, patients with ovarian, multiple myeloma,
anal, hepatobiliary and renal cancer tended to report
worse experiences compared with patients with other
gynaecological, haematological, upper gastrointestinal
and urological cancers respectively.
The observed socio-demographic differences in experi-
ence are concordant with other patient survey evidence
(note: not necessarily from patients with cancer) generally
suggesting that younger and ethnic minority patients and
women provide more critical evaluations of their care
(Campbell et al. 2001; Weech-Maldonado et al. 2003;
Mead & Roland 2009; Goldstein et al. 2010; Elliott et al.
2012; Lyratzopoulos et al. 2012a). There are only few pre-
vious reports of experience surveys specific to patients
with cancer. A US study of the experience of patients with
lung and colorectal cancer also indicates worse experi-
ences by ethnic minority patients (Ayanian et al. 2010).
Using data from the English Cancer Patient Experience
surveys, inequalities in the experience of promptness of
diagnostic suspicion in primary care, shared decision
making and ‘overall’ evaluation of care have been previ-
ously reported (Lyratzopoulos et al. 2012b; El Turabi et al.
2013; Bone et al. 2014). The present study substantially
amplifies these previous analyses as it explores variation
in experience across every survey question and all experi-
ence domains (including the experience of diagnosis, treat-
ment and community care, across 64 items). In spite of the
observed inequalities among different patient groups, hos-
pital performance in respect of cancer patient experience
scores is only marginally affected by patient case-mix; this
finding principally reflects the homogeneity of patient
case-mix among most English hospitals (Abel et al. 2014).
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Strengths of our study include its high (for a postal
patient survey) response rate; its nationwide sample; its
large population; the inclusion of patients with any type of
cancer; and the relatively high completeness of informa-
tion on exposure variables. Certain limitations ought to
also be borne in mind in interpretation. We had no infor-
mation on a range of variables that may influence experi-
ence, for example, on health performance status, or the
influence of the actual treatments and care experienced by
the patients (Ayanian et al. 2010). It should also be noted
that the proportion of patients in active treatment or in
remission (under surveillance) will vary across cancers.
Box 1. Summary of disparities in the experience of patients with cancer by cancer diagnosis and socio-demographic
characteristics (full visual summary of results in Tables 3 and 4 and Appendix 3).
Age: Poor experience across the cancer patient journey is consistently more common among younger ages than older
groups, and decreases in older age groups. This is particularly consistent for questions relating to experience of inpatient
hospital care. However, there are some notable exceptions.
• Very old patients (i.e., aged 85+) tend to report slightly poorer experience than 75–84-year-olds.
• Younger patients more often report a positive experience for questions relating to provision of information or
explanation than older patients, for example regarding treatment side effects (questions 17–18). They also report more
positive experience of being offered financial support (question 25) and experience of cancer research (questions 27–29).
Gender: Women consistently report poor cancer patient experience more often than men. After adjustment for age,
ethnicity and cancer, this gender inequality becomes more apparent than it could be appreciated by simply observing
crude patterns of variation. This is partly explained by the overall positive experience of women with breast cancer,
masking the poorer experience of female patients with cancer overall.
Ethnic group: Patients from White ethnic groups report more positive experiences than patients from ethnic minority
groups. The only question where patients from all ethnic minority groups had a more positive experience was for the
provision of a written care plan (question 68). Chinese ethnic group patients report the worst experience across most
questions.
Deprivation: There was evidence of (relatively small) disparities in patient experience by socio-economic group for
about half the survey items; however, there is no consistent pattern in the direction of this effect.
Cancer diagnosis: Positive experiences are most often reported among patients with ductal carcinoma in situ, breast,
melanoma, endometrial, cervical and testicular cancers. It should be noted that in crude analysis, two of these cancers
(cervical and testicular) are associated with relatively poor reported experience, before adjustment is made for age and
other variables (Appendix 5). On the other hand, positive experience was least often reported by patients with anal,
pancreatic, renal and hepatobiliary/gall bladder cancers and multiple myeloma.
• There are disparities among specialty groups, for example we note particularly that overall inpatient experience
(questions 31–54) among patients with gynaecological cancers is more often positive than for patients with lower
gastrointestinal cancers.
• There are also substantial disparities within cancer specialty groups, consistent across questions.
• Finally, there are a few notable associations for individual questions, for example, patients with mesothelioma are
very likely to report positive experiences of information about financial support (question 25), reflecting established
statutory compensation schemes for this occupational cancer.
• There are only a few questions where the overall patterns of inequality in experience by cancer differ from the general
trend. Experience of cancer research (question 27) is one of these; this is perhaps explained by patients with common
cancers (such as breast cancer) being less likely to be invited to take part in research than patients with rarer cancers,
where the pool of potential research participants is smaller. Experience of outpatient waiting times (question 61) is
a further question where inequalities do not follow the general pattern of variation by cancer, but overall variation
in experience of outpatient waiting times is not strongly associated with any particular diagnosis.
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Even in the context of a survey with a relatively high
response rate, there is potential for non-response bias.
Specifically regarding the overall summary analysis of
inequalities by caner type, it should be noted that it is based
on a linear regression model, which essentially represents
the adjusted mean variation by cancer across all survey
questions. These mean-reported values are therefore sus-
ceptible to the influence of outliers and for some cancers,
the mean variation in experience may not be the same as
the typical variation (e.g., as observed for patients with
mesothelioma). In order to characterise variation across all
survey questions, it was necessary to consider a large
number of models (i.e., for each outcome). We have made
no attempt to correct for multiple testing as this concern is
inapplicable. Standard corrections for multiple testing are
designed to avoid undue attention being given to a small
number of significant results that are observed when a large
number of tests are considered (often also assuming that
tests are independent). This consideration does not apply
here as almost all associations presented are statistically
significant, which strongly argues against chance findings.
Length of time since diagnosis may also differentially influ-
ence recall of care experiences; however, previous work
found minimal differences in overall patterns of variation
by cancer when restricting the analysis to patients diag-
nosed within the last year (Lyratzopoulos et al. 2012b).
Being diagnosed with cancer in a young age is associated
with particular practical and psychological difficulties
(NICE 2005; Harrison et al. 2009; IOM 2013). It is therefore
plausible that younger patients have greater needs for infor-
mation about their tests, condition and treatment, and com-
munication with their providers. Our findings would
indicate that these needs are on the whole not currently
being fully met. It is, however, encouraging that, against the
overall pattern of differences in experience by age, younger
patients reported better experiences in respect of informa-
tion about their treatment, access to a specialist nurse,
information about access to peer and financial support, and
participation in cancer research (questions 15, 20, 24, 25 and
27 respectively), concordant with national guidance sup-
porting access to key workers and participation to clinical
trials for young patients with cancer (NICE 2005).
Inequalities in experience among different socio-
demographic groups, and particularly among patients of
different ethnicity, may reflect either variation in actual
provision of care or differences in expectations of quality
(the so-called ‘same care worse experience’ hypothesis)
(Mead & Roland 2009; Lyratzopoulos et al. 2012a). Under-
standing the proportion of inequalities that is due to either
of these two potential sources of variation is evidently
critical for helping to inform appropriate improvement
strategies. Distinguishing among differences in expecta-
tions of quality and actual differences in delivered care is,
however, challenging, and it is likely that ethnic differ-
ences in patient experience may be the result of both
differences in expectations of care quality and the care
that is actually delivered (Mead & Roland 2009; Weinick
et al. 2011; Lyratzopoulos et al. 2012a; Saunders et al.
2014). Communication difficulties, either because of dif-
ferences in socio-cultural norms of medical consultation
or language barriers, can commonly result in poorer
experience. Use of translators for patients with limited
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Figure 1. Association between cancer
diagnosis and overall patient experience
(average) across the survey/patient
journey. Results are compared with the
experience of patients with rectal cancer
as a baseline, with a lower odds ratio indi-
cating more positive experiences. Oph-
thalmic and rarer CNS, ophthalmic and
rarer central nervous system; Gynaeco-
logical NOS, gynaecological not otherwise
specified.
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English language skills can help to improve communica-
tion and satisfaction with care (Karliner et al. 2007). Hos-
pitals with higher levels of ‘cultural competency’ scores
have lower levels of ethnic disparity in patient experience
(Weech-Maldonado et al. 2012).
We observed substantial inequalities in experience
among patients with different cancer diagnoses. It would be
unreasonable to assume that, after adjusting for age, gender
and ethnicity, patients with different cancers have differ-
ent prior expectations of care quality. It is theoretically
possible that some of the differences may relate to inequali-
ties in the quality of care provided by different specialist
services (e.g., haematology compared with urology).
However, notable inequalities in experience are observed
even between patients with different cancers treated by the
same clinical specialty and MDT service environments.
Therefore, the observed differences in experience among
patients with different cancers are likely to chiefly reflect
disease-specific factors; differences in the promptness of
diagnosis, treatment burden and prognosis are likely to be
important contributors. For example, among patients with
haematological cancers, those with multiple myeloma
report the most critical experience, and they are also the
patients who are likely to have experienced a greater
number of pre-referral consultations with a general practi-
tioner with relevant symptoms (Lyratzopoulos et al.
2012b, 2013). Similarly, among patients with lower gastro-
intestinal tract cancers, those with anal cancer tend to
report the most critical experiences, possibly a reflection of
associated treatment burden, as (compared with patients
with colon cancer). Appreciation of worse prognosis may
also be a factor, as advanced stage is associated with poorer
experience of cancer care (Ayanian et al. 2010). Independ-
ent of their exact causes (in respect of the precise influence
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Figure 2. Association between cancer diagnosis and overall patient experience across the patient journey. Results are presented making
comparisons in experience among cancer diagnoses within cancer specialty group. A lower odds ratio indicates more positive experiences.
P-values are presented, and are a Wald test of whether odds ratios vary within cancer specialty group. Ophthalmic and rarer CNS,
ophthalmic and rarer central nervous system; Gynaecological NOS, gynaecological not otherwise specified.
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of promptness of diagnosis, treatment burden and progno-
sis), large within specialty group variations in experience
should be considered as indicators of different healthcare
needs of patients with different diagnoses. Specialty teams
may therefore be able to prioritise interventions to improve
the experience of their patients specifically targeting those
patients within their specialty with greater needs for
patient-centred care. Such interventions can, for example,
include the provision of additional information and emo-
tional or peer-support, or additional access and time for
communication with nurses or doctors, for patients with
diagnoses that confer a higher risk of poorer experience.
Although the findings are broadly consistent across the
survey, appreciation of patterns of variation in respect of
each question (Tables 3 and 4) may help to identify priori-
ties for improving specific aspects of experience for differ-
ent patient groups. Given the findings, oncology teams
specialising in gynaecological, haematological, gastroin-
testinal and urological cancers could prioritise the devel-
opment and evaluation of interventions to improve the
experience of patients with ovarian, multiple myeloma,
anal, hepatobiliary and renal cancer respectively.
In conclusion, we report inequalities in experience
among patients with cancer with different characteristics
and diagnosis. The findings could guide improvement
efforts targeting patients with cancer who are at greater
risk of poorer experience of care. Specialty teams may be
able to provide additional (targeted and tailored) support to
improve the experience of patients with those cancers
associated with greater care needs. Data from the English
Cancer Patient Experience Survey provide an example of
how nationwide surveys can provide intelligence to help
inform and motivate both national and local initiatives to
improve the care experience of patients with cancer. Iden-
tifying patterns of variation that we describe in other
country populations and healthcare settings will be par-
ticularly useful.
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Appendix 1. Questions, item response and score for all questions.
Appendix 2. Cancer ICD-10 codes, diagnosis groups and MDT classifications.
Appendix 3. Association between cancer diagnosis and patient experience. Cancers arranged in specialty groups, and
sorted within specialty by ranked experience.
Appendix 4. Adjusted percentage of patients reporting a negative experience of care (question 70) results come from the
model for which odds ratios are presented in Table 2.
Appendix 5. Unadjusted and adjusted association between patient socio-demographic characteristics and experience
(average measure across all survey questions/the whole patient journey).
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Appendix 6. Unadjusted and adjusted association between patient cancer diagnosis and experience (average measure
across all survey questions/the whole patient journey).
Appendix 7. Adjusted ORs for ‘overall’ experience by cancer diagnosis (average measure across all survey questions/the
whole patient journey).
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